SAM
CLDX icon

Simplify Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Simplify Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
53,134
-15,860
-23% -$512K 0.03% 61
2026
Q1 		$2.19M Sell
68,994
-16,006
-19% -$436K 0.03% 52
2025
Q4 		$2.31M Hold
85,000
– – 0.04% 59
2025
Q3 		$2.2M Buy
+85,000
New +$1.97M 0.04% 48

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Simplify Asset Management's CLDX Position: Q2 2026 in Review

Simplify Asset Management reduced its Celldex Therapeutics (CLDX) stake by 23% in Q2 2026, selling an estimated $512K and leaving 53,134 shares worth $1.98M. The position accounts for 0.03% of the portfolio, ranked #61.

Simplify Asset Management first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.31M in Q4 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Simplify Asset Management held 53,134 shares of Celldex Therapeutics worth $1.98M as of Q2 2026.
  • Simplify Asset Management sold 15,860 Celldex Therapeutics shares in Q2 2026, an estimated $512K.
  • Celldex Therapeutics made up 0.03% of Simplify Asset Management's portfolio in Q2 2026, its #61 holding.
  • Simplify Asset Management first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Simplify Asset Management's Celldex Therapeutics position peaked at $2.31M in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.